Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Cantor Fitzgerald
UBS
Chubb
Colorcon
AstraZeneca
Boehringer Ingelheim
Medtronic
McKinsey

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 4,215,104

« Back to Dashboard

Summary for Patent: 4,215,104
Title: Multi-fractionable tablet structure
Abstract:The invention disclosed provides a multi-fractionable tablet structure initially configurated in a unitary dosage while having readily severable sub-dosage units as components thereof. Score markings are positioned variously about the tablet both along the top and bottom surfaces of an approximately rectangular configuration whereas in preferred embodiments thereof, score markings additionally appear along opposite vertical side surfaces of the tablet. Special placement of the score markings readily permit at least either an accurate bisectional fracture or accurate trisectional fracture of the tablet as may be desired for patient consumption.
Inventor(s): Ullman; Michael K. (Evansville, IN), David; Stephen T. (Evansville, IN), Gallian; Claude E. (Evansville, IN)
Assignee: Mead Johnson & Company (Evansville, IN)
Application Number:06/024,139
Patent Claim Types:
see list of patent claims
Dosage form;

Drugs Protected by US Patent 4,215,104

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Julphar
Mallinckrodt
Teva
Colorcon
Boehringer Ingelheim
Daiichi Sankyo
Federal Trade Commission
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.